Analysis of chemotherapeutic response heterogeneity and drug clustering based on mechanism of action using an in vitro assay

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 2805-2811

  Rice, Shara D ^a   Heinzman, Jamie M ^a   Brower, Stacey L ^a   Ervin, Paul R ^a   Song, Nan ^a   Shen, Kui ^a   Wang, Dakun ^a  

^a Precision Therapeutics Inc   (United States)

Author keywords

Cancer; ChemoFx DRM; Chemotherapeutic response; Chemotherapy drug response marker; Heterogeneity; In vitro chemosensitivity testing; Mechanism of action

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; PACLITAXEL;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL HETEROGENEITY; CLUSTER ANALYSIS; COLON CANCER; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG CANCER; MULTIPLE CANCER; OVARY CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; NEOPLASMS; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; REPRODUCIBILITY OF RESULTS; TAXOIDS;

EID: 77955829898     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, Gilde K, Camerini R and Cognetti F: Large randomized study of thymosin 1, interferon alfa, or both in combination with cacarbazine in patients with metastatic melanoma. J Clin Oncol 2010.
2. Hirooka M, Koizumi Y, Kisaka Y, Abe M, Murakami H, Matsuura B, Hiasa Y and Onji M: Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus. Am J Roentgenol 194: W221-226, 2010.
3. Bardia A, Loprinzi C, Grothey A, Nelson G, Alberts S, Menon S, Thome S, Gill S and Sargent D: Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. Semin Oncol 7: 39-46, 2010.
4. Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, Shao ZM, Shen ZZ and Shen KW: Weekly paclitaxel plus carboplatin is an effective nonanthracycline- containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol 2010.
5. Rydzewska L, Tierney J, Vale CL and Symonds PR: Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 20: CD007406, 2010.
6. Lewis JD, Chagpar AB, Shaughnessy EA, Nurko J, McMasters K and Edwards MJ: Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer 2010.
7. Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010.
8. Shih KK, Chi DS, Barakat RR and Leitao MM Jr: Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: An updated series. Gynecol Oncol 2010.
9. Homayounfar K, Liersch T, Niessner M, Meller J, Lorf T, Becker H and Ghadimi BM: Multimodal treatment options for bilobar colorectal liver metastases. Langenbecks Arch Surg 2010.
10. Gerber B, Freund M and Reimer T: Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int 107: 85-91, 2010.
11. Stathis A, Moore MJ: Advanced pancreatic carcinoma: current treatment and future challenges. Nature Rev Clin Oncol 5: 163- 72, 2010.
12. Kim HS, Park NH, Kang S, Seo SS, Chung HH, Kim JW, Song YS and Kang SB: Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. J Obstet Gynecol Res 36: 86-93, 2010.
13. Cameron D, Bell R, Aapro M and Zielinski C: What are the current standards of care and recent developments in the management of breast cancer? Oncologist 11(suppl 1): 1-3, 2006.
14. Stordal B, Pavlakis N and Davey R: A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev 33: 688-703, 2007. (Pubitemid 350089290)
15. Taheri M, Mahjoubi F and Omranipour R: Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet Mol Res 9: 34-40, 2010.
16. Schilsky RL: Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 9: 363-366, 2010.
17. Wu C, Xu B, Yuan P, Ott J, Guan Y, Liu Y, Liu Z, Shen Y, Yu D and Lin D. Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small cell lung cancer. Pharmacogenet Genomics 20: 389- 95, 2010.
18. MI Z, Holmes FA, Hellerstedt B, Pippen J, Collea R, Backner A, Bush JE, Gallion HH, Wells A and O'Shaughnessy JA: Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Res 25: 1733-1740, 2008.
19. Brewer SL, Fensterer JE and Bush JE: The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy. In: Methods in Molecular Biology; Apoptosis and Cancer: Methods and Protocols. Mor G and Alvero AF (eds.). Totowa NJ, Humana Press, pp. 57-78, 2008.
20. Heinzman JM, Brewer SL, Bush JE and Silverman JF: Ex vivo enrichment of malignant carcinoma cells in primary culture. Pathology 39: 491-494, 2007.
21. Heinzman JM, Rice SD and Corkan LA: Robotic liquid handlers and semi-automated cell quantification systems increase consistency and reproducibility in high-throughput, cell-based assay. JALA 75: 7-14, 2010.
22. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S and van de Vijver MJ: Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 55: 406-412, 2003. (Pubitemid 36308152)
23. Shih IeM and Davidson B: Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol 5: 1641-1657, 2009.